Hemogenyx Pharmaceuticals innovates brain cancer treatment with CBR delivery
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by demonstrating the ability to deliver its proprietary Chimeric Bait Receptor (CBR) into the brain via programmed microglial cells. This innovative approach opens new doors for the potential treatment of brain cancers and certain neurodegenerative diseases, tackling the […]